TRAIL and DcR1 Expressions Are Differentially Regulated in the Pancreatic Islets of STZ- versus CY-Applied NOD Mice
Figure 3
Histologic examination of the pancreatic islets of STZ- or CY-treated NOD mice for TRAIL ligand expression. NOD mice received single intraperitoneal injections of 150 mg/kg STZ or 200 mg/kg CY. Pancreata were isolated at days 0, 2, 4, 7, 11, and 14 in the STZ group, and at days 0, 1, 4, 7, 14, and 21 in the CY group. Three mice were sacrificed at each point. Representative images are shown for negative, weak, moderate, and strong stainings for the TRAIL ligand expression. (a) Sample stainings for STZ-treated mice are shown through (A)–(D), and for CY-treated mice through (E)–(H): (A) and (E) show negative staining for TRAIL in the pancreatic islet in the STZ- and CY-treated groups, respectively; the surrounding acinar cells display weak IC staining (arrow) in (A). Weak IC (B), moderate IC (C), and strong nuclear (D) positivity in the pancreatic islets. Acinar cells display strong nuclear positivity in (D); (F) presents weak (thin arrow) and moderate (thick arrow) IC stainings within the islet, (G) moderate (thin arrow) and strong (thick arrow) IC positivity in the islet, (H) moderate IC and strong nuclear staining in majority of the islet, and moderate nuclear positivity in acinar cells. Control staining (secondary antibody only) is shown in (I). Smaller islets are depicted at 400X magnification for clarity, while other images were taken at 200x. (b) Immunohistochemical staining results for TRAIL were evaluated as described in Section 2. Changes at days 2, 4, and 14 observed in the STZ group, and the alteration observed at day 14 in the CY group were statistically significant (). Error bars represent ±SEM. IC: intracytoplasmic.
